A kind of aspirin composition and preparation method for treating coronary heart disease

Abstract

The invention discloses an aspirin composition for treating coronary heart disease and a preparation method thereof. The components and parts by weight of the composition include: 3-7 parts of aspirin, 20-25 parts of pinellia chinensis, 30-35 parts of agarwood, radish 60-70 parts of seeds, 35-40 parts of ginger, 25-30 parts of Chuanwu, 50-60 parts of red dates, and 80-100 parts of medicinal excipients. The preparation method includes material preparation, extraction of active ingredients of traditional Chinese medicine raw materials, granulation, granulation, and tabletting. The composition can not only treat coronary heart disease, but also invigorate the stomach. The synergistic effect of Pinellia, ginger, Aconitum, Agarwood, radish seeds, and red dates can improve the functions of the spleen, stomach, and intestines, and help the absorption of aspirin and the medicinal properties of aspirin. effective play. Red dates and ginger can reduce the toxic and side effects of aspirin, pinellia, ginger, aconitum, agarwood, radish seeds, etc. The composition is a sustained-release preparation, once a day, convenient to take, and beneficial to improve the compliance of patients.

Description

technical field [0001] The present invention relates to the field of compositions used in combination with Chinese and Western medicines, in particular to an aspirin composition for treating coronary heart disease and a preparation method thereof Background technique [0002] Aspirin is the earliest antiplatelet drug used in antithrombotic therapy, and has been established as a classic drug for the treatment of acute myocardial infarction (AMI), unstable angina and secondary prevention of myocardial infarction (MI). The principle of action is that aspirin irreversibly acetylates the hydroxyl group of the 529th serine residue in the COX-1 active site polypeptide chain in the cyclooxygenase, leading to the inactivation of COX, and then blocking the conversion of AA into thromboxane A2 (TXA2) pathway to inhibit PLT aggregation. COXs are the key rate-limiting enzymes in the process of producing TXA2 and prostaglandin I2 (PGI2) from AA. There are two forms of COX-1 and COX-2 in ...

AI Technical Summary

Problems solved by technology

[0004] In order to overcome the damage of aspirin to the gastric mucosa, some people make aspirin into enteric-coated tablets. Enteric-coated tablets avoid the direct stimulation of aspirin to the gastric mucosa, but they cannot solve the stimulation of aspirin to the intestinal mucosa, and the general patients with coronary heart disease who need long-term medication For the elderly over 50 years old, the elderly's gastrointestinal function is relatively weak, or they suffer from chronic gastroenteritis, etc.

Images